VAL201, which is currently in a phase I/II clinical study, already has patent protection in other markets around the world.
The compound works to prevent tumour growth by specifically inhibiting the proliferation of tumour cells. Its inhibitory effects on lymph node metastases have been demonstrated in the pre-clinical prostate cancer model.
In the ongoing clinical trial, VAL201 has so far shown itself to be well-tolerated, with “signs of activity” in advanced prostate cancer noted through biomarker and imaging techniques.
“With previously granted worldwide rights for the use of VAL201 in prostate cancer, we are very pleased that the US Patent and Trademark Office has allowed claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer,” said chief executive Satu Vainikka.
“I believe that not only will the allowed claims complement our other intellectual property and provide the company with a more compelling package to offer when in discussions with big pharma, but I also believe that if we can reduce the symptoms and progression of metastases, as well as targeting the lesion, through the use of VAL201, we can improve prospects for patients.”
In Wednesday afternoon trading, ValiRxshares were down 7.1% to 0.21p.
--Adds share price--